Cancer Medicine

Papers
(The TQCC of Cancer Medicine is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Sarcopenia and adverse health‐related outcomes: An umbrella review of meta‐analyses of observational studies123
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker85
Development and validation of an immune‐related prognostic signature in lung adenocarcinoma73
Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma72
Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer70
Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy70
Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index70
Changing trends in the disease burden of esophageal cancer in China from 1990 to 2017 and its predicted level in 25 years68
Enhancement of tumor lethality of ROS in photodynamic therapy67
Global trends in the incidence and mortality of esophageal cancer from 1990 to 201765
Perspectives, fears and expectations of patients with gynaecological cancers during the COVID‐19 pandemic: A Pan‐European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe61
Role of the oral microbiota in cancer evolution and progression59
Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma58
Depression and prostate cancer risk: A Mendelian randomization study56
Disparities in telemedicine during COVID‐1956
Patient and clinician experience of a serious illness conversation guide in oncology: A descriptive analysis55
Artificial intelligence in oncology: Path to implementation53
Chinese and global burdens of gastric cancer from 1990 to 201953
Chemokines and chemokine receptors: A new strategy for breast cancer therapy51
Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis51
Exosome‐mediated delivery of miR‐204‐5p inhibits tumor growth and chemoresistance51
Global, regional and national incidence, mortality and disability‐adjusted life‐years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 201950
The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population‐based retrospective matched cohort analysis48
Machine Learning techniques in breast cancer prognosis prediction: A primary evaluation48
Comprehensive review of implications of COVID‐19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic48
Exosomal miRNAs as biomarkers for diagnostic and prognostic in lung cancer47
Safety and efficacy of photobiomodulation therapy in oncology: A systematic review46
Exosomal Sonic Hedgehog derived from cancer‐associated fibroblasts promotes proliferation and migration of esophageal squamous cell carcinoma46
AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer46
The immune phenotype of tongue squamous cell carcinoma predicts early relapse and poor prognosis46
An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle‐invasive bladder cancer (MIBC)45
Magnetically driven microfluidics for isolation of circulating tumor cells44
Nomogram for predicting overall survival in stage II‐III colorectal cancer44
Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy44
Symptom clusters experienced by breast cancer patients at various treatment stages: A systematic review43
Impact of delayed treatment in women diagnosed with breast cancer: A population‐based study43
COVID‐19 and Oncology: Service transformation during pandemic43
Quantitative ultrasound radiomics in predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from multi‐institutional study43
Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China42
Exosomes released from M2 macrophages transfer miR‐221‐3p contributed to EOC progression through targeting CDKN1B42
Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer42
Relationship of established risk factors with breast cancer subtypes42
METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma42
Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial42
Exosomal lncRNA H19 promotes the progression of hepatocellular carcinoma treated with Propofol via miR‐520a‐3p/LIMK1 axis40
The prognostic utility of pre‐treatment neutrophil‐to‐lymphocyte‐ratio (NLR) in colorectal cancer: A systematic review and meta‐analysis40
Construction of a lipid metabolism‐related and immune‐associated prognostic signature for hepatocellular carcinoma40
The effect of anticancer treatment on cancer patients with COVID‐19: A systematic review and meta‐analysis39
Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial39
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades38
The artificial intelligence‐assisted cytology diagnostic system in large‐scale cervical cancer screening: A population‐based cohort study of 0.7 million women38
Prehabilitation exercise therapy for cancer: A systematic review and meta‐analysis37
Global, regional, and national burden and quality of care index (QCI) of thyroid cancer: A systematic analysis of the Global Burden of Disease Study 1990–201737
Perspectives and controversies regarding the use of natural products for the treatment of lung cancer36
BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway35
Convalescent Plasma for the Treatment of Severe COVID‐19 Infection in Cancer Patients35
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer35
Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy35
Integrated bioinformatics analysis of expression and gene regulation network of COL12A1 in colorectal cancer35
Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors34
Results from a randomized controlled trial testing StressProffen; an application‐based stress‐management intervention for cancer survivors34
Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma33
Once‐a‐week or every‐other‐day urethra‐sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow‐up results33
Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 201933
Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer33
Esophageal cancer: trends in incidence and mortality in China from 2005 to 201533
Surgical resection of symptomatic brain metastases improves the clinical status and facilitates further treatment32
Machine learning for the prediction of bone metastasis in patients with newly diagnosed thyroid cancer32
Tamoxifen is a candidate first‐in‐class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells—Unrecognized players in tumorigenesis32
Pattern and prognosis of distant metastases in nasopharyngeal carcinoma: A large‐population retrospective analysis32
A signature of 33 immune‐related gene pairs predicts clinical outcome in hepatocellular carcinoma32
Exosomal microRNA‐4661‐5p–based serum panel as a potential diagnostic biomarker for early‐stage hepatocellular carcinoma32
Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next‐generation sequencing technique31
Downregulated hsa_circ_0077837 and hsa_circ_0004826, facilitate bladder cancer progression and predict poor prognosis for bladder cancer patients31
Insulin‐like growth factor‐1 and site‐specific cancers: A Mendelian randomization study31
Examining the association among fear of COVID‐19, psychological distress, and delays in cancer care31
Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab31
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients30
TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatment30
MRI‐based radiomics nomogram to predict synchronous liver metastasis in primary rectal cancer patients30
Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm30
Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma30
Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer30
Exosome–transmitted microRNA‐133b inhibited bladder cancer proliferation by upregulating dual‐specificity protein phosphatase 130
Helicobacter pylori‐related risk predictors of gastric cancer: The latest models, challenges, and future prospects29
LncRNA PITPNA‐AS1 boosts the proliferation and migration of lung squamous cell carcinoma cells by recruiting TAF15 to stabilize HMGB3 mRNA29
The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice29
Prevalence and severity of long‐term physical, emotional, and cognitive fatigue across 15 different cancer entities29
Circ‐PGAM1 promotes malignant progression of epithelial ovarian cancer through regulation of the miR‐542‐3p/CDC5L/PEAK1 pathway29
The roles of ferroptosis regulatory gene SLC7A11 in renal cell carcinoma: A multi‐omics study28
COVID‐19 pandemic and impact on cancer clinical trials: An academic medical center perspective28
Geriatric assessment domains to predict overall survival in older cancer patients: An analysis of functional status, comorbidities, and nutritional status as prognostic factors28
The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the Global Burden of Disease Study28
Cell‐free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience28
Exosomal lncRNA FAM225A accelerates esophageal squamous cell carcinoma progression and angiogenesis via sponging miR‐206 to upregulate NETO2 and FOXP1 expression28
miR‐140‐3p inhibits colorectal cancer progression and its liver metastasis by targeting BCL9 and BCL228
Circular RNA hsa_circRNA_102209 promotes the growth and metastasis of colorectal cancer through miR‐761‐mediated Ras and Rab interactor 1 signaling27
TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma27
LncRNA SNHG3 sponges miR‐577 to up‐regulate SMURF1 expression in prostate cancer27
Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation27
The cancer patient’s perspective of COVID‐19‐induced distress—A cross‐sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic27
Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee27
How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring r27
First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study27
LncRNA MALAT1 accelerates non‐small cell lung cancer progression via regulating miR‐185‐5p/MDM4 axis27
Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma27
COVID‐19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment27
TIGIT enhances CD4+ regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer model26
The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels26
Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis26
LncRNA NUTM2A‐AS1 positively modulates TET1 and HIF‐1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR‐376a26
Galangin promotes cell apoptosis through suppression of H19 expression in hepatocellular carcinoma cells26
Bcl‐2/Bcl‐xl inhibitor APG‐1252‐M1 is a promising therapeutic strategy for gastric carcinoma26
Long noncoding RNA HCG18 up‐regulates the expression of WIPF1 and YAP/TAZ by inhibiting miR‐141‐3p in gastric cancer26
Resveratrol suppresses the growth and metastatic potential of cervical cancer by inhibiting STAT3Tyr705 phosphorylation26
Development and validation of MRI‐based deep learning models for prediction of microsatellite instability in rectal cancer26
MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria26
A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort26
Risk factors and predictors of lymph nodes metastasis and distant metastasis in newly diagnosed T1 colorectal cancer26
Trends in the incidence of head and neck cancer by subsite between 1993 and 2015 in Japan25
Immunotherapies for hepatocellular carcinoma25
LncRNA LINC00857 regulates the progression and glycolysis in ovarian cancer by modulating the Hippo signaling pathway25
225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models25
Efficacy of intravesical therapies on the prevention of recurrence and progression of non‐muscle‐invasive bladder cancer: A systematic review and network meta‐analysis25
Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials25
Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy25
Identification of aberrantly methylated differentially expressed genes and associated pathways in endometrial cancer using integrated bioinformatic analysis25
Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta‐analysis25
Exosome‐transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma25
Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer25
A systematic review and meta‐analysis of the prognostic role of age in oral tongue cancer25
A population study of screening history and diagnostic outcomes of women with invasive cervical cancer25
Long noncoding RNA MSC‐AS1 promotes hepatocellular carcinoma oncogenesis via inducing the expression of phosphoglycerate kinase 124
Covid‐19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany24
Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening24
Long noncoding RNA MCM3AP‐AS1 enhances cell proliferation and metastasis in colorectal cancer by regulating miR‐193a‐5p/SENP124
Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients24
A practical nomogram and risk stratification system predicting the cancer‐specific survival for patients with early hepatocellular carcinoma24
Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial‐ethnic group, United States 2003‐201624
Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use24
Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection24
SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3/CDT1 axis24
Real‐world outcomes of chemoradiotherapy for unresectable Stage III non‐small cell lung cancer: The SOLUTION study24
Disparities in cancer‐related healthcare among people with intellectual disabilities: A population‐based cohort study with health insurance claims data24
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial24
Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC24
Radiation therapy and secondary malignancy in Li‐Fraumeni syndrome: A hereditary cancer registry study23
Checkpoint inhibitor/interleukin‐based combination therapy of cancer23
nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients23
EO771, is it a well‐characterized cell line for mouse mammary cancer model? Limit and uncertainty23
Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and pancreatic cancer incidence and mortality: A prospective cohort study23
MiR‐646 suppresses proliferation and metastasis of non‐small cell lung cancer by repressing FGF2 and CCND223
A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma23
EBV‐positive B‐cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency23
Stromal score as a prognostic factor in primary gastric cancer and close association with tumor immune microenvironment23
A novel five‐gene signature predicts overall survival of patients with hepatocellular carcinoma23
SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR‐23b‐3p via sponging EGR1 in hepatocellular carcinoma23
Long‐term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy23
Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium23
Circular RNA: A promising new star for the diagnosis and treatment of colorectal cancer23
HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR323
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomi23
Impact of adjuvant chemotherapy on outcomes in appendiceal cancer23
Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists22
Long noncoding RNA UCA1 promotes cell growth, migration, and invasion by targeting miR‐143‐3p in oral squamous cell carcinoma22
Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy—A retrospective cohort study22
The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively22
Role of tumor microenvironment in cancer progression and therapeutic strategy22
Circ‐UBAP2 functions as sponges of miR‐1205 and miR‐382 to promote glioma progression by modulating STC1 expression22
BRAF mutation and its inhibitors in sarcoma treatment22
Comprehensive analysis of pan‐cancer reveals potential of ASF1B as a prognostic and immunological biomarker22
Seven immune‐related genes prognostic power and correlation with tumor‐infiltrating immune cells in hepatocellular carcinoma22
Long noncoding RNA HCG11 inhibited growth and invasion in cervical cancer by sponging miR‐942‐5p and targeting GFI122
Sex differences in solid pseudopapillary neoplasm of the pancreas: A population‐based study22
Association of image‐defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma22
The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues22
PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence22
Diagnostic significance and carcinogenic mechanism of pan‐cancer gene POU5F1 in liver hepatocellular carcinoma22
Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma22
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer22
Usefulness of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenoc22
MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer22
Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels21
Impact of early palliative care according to baseline symptom severity: Secondary analysis of a cluster‐randomized controlled trial in patients with advanced cancer21
Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer21
Epithelial‐mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP121
The lncRNA XIST/miR‐125b‐2‐3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer21
Lidocaine inhibits the metastatic potential of ovarian cancer by blocking NaV1.5‐mediated EMT and FAK/Paxillin signaling pathway21
Prediction of lung metastases in thyroid cancer using machine learning based on SEER database21
N6‐methyladenine‐related genes affect biological behavior and the prognosis of glioma21
The immune landscape during the tumorigenesis of cervical cancer21
Intratumor heterogeneity: A new perspective on colorectal cancer research21
Retracted: Circ‐SPECC1 modulates TGFβ2 and autophagy under oxidative stress by sponging miR‐33a to promote hepatocellular carcinoma tumorigenesis21
Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients21
Identification and validation of a ferroptosis‐related gene signature for predicting survival in skin cutaneous melanoma20
Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer20
Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib20
LncRNA TMPO‐AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR‐329‐3p to stimulate FOXK1‐mediated AKT/mTOR signaling pathway20
Metabolomic effects of androgen deprivation therapy treatment for prostate cancer20
Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma20
Discovery of novel molecular characteristics and cellular biological properties in ameloblastoma20
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types20
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer20
Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV‐related hepatocellular carcinoma20
Clinical implications of next‐generation sequencing‐based panel tests for malignant ovarian tumors20
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature20
Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis20
Comprehensive molecular profiling broadens treatment options for breast cancer patients20
Age‐specific prevalence and determinants of depression in long‐term breast cancer survivors compared to female population controls20
Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma‐associated antigen‐A3 expression through Yes‐associated protein inactivation20
Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression20
Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer20
Decreasing trends in thyroid cancer incidence in South Korea: What happened in South Korea?20
Serum N‐Glycome analysis reveals pancreatic cancer disease signatures20
Development and validation of a pretreatment nomogram to predict overall survival in gastric cancer20
Predictive role of diffusion‐weighted whole‐body MRI (DW‐MRI) imaging response according to MY‐RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined e20
The clinical application value of mixed‐reality‐assisted surgical navigation for laparoscopic nephrectomy20
Using deep learning to identify bladder cancers with FGFR‐activating mutations from histology images20
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis20
Selecting human papillomavirus genotypes to optimize the performance of screening tests among South African women20
HOXD9 promote epithelial‐mesenchymal transition and metastasis in colorectal carcinoma19
miR‐18a activates Wnt pathway in ER‐positive breast cancer and is associated with poor prognosis19
A multicentre cross‐sectional observational study of cancer multidisciplinary teams: Analysis of team decision making19
Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy19
Indocyanine green is a sensitive adjunct in the identification and surgical management of local and metastatic hepatoblastoma19
Long noncoding RNA FOXD2‐AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR‐206/MAP3K1 axis19
Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti‐Lag‐3 via reducing FGL1 expression19
WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma19
Long noncoding RNA DUXAP8 contributes to the progression of hepatocellular carcinoma via regulating miR‐422a/PDK2 axis19
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer19
Comparison of vaginal microbiota in gynecologic cancer patients pre‐ and post‐radiation therapy and healthy women19
Delayed presentation, diagnosis, and psychosocial aspects of male breast cancer19
Marital status and survival in cancer patients: A systematic review and meta‐analysis19
Association between pre‐diagnostic serum albumin and cancer risk: Results from a prospective population‐based study19
Incidence and survival of rare cancers in the US and Europe19
Identification of novel subtypes based on ssGSEA in immune‐related prognostic signature for tongue squamous cell carcinoma19
Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non–muscle‐invasive bladder cancer (NMIBC): A cohort analysis19
The underlying mechanisms of lorlatinib penetration across the bloodbrain barrier and the distribution characteristics of lorlatinib in the brain19
Correlation of tumor‐infiltrating immune cells of melanoma with overall survival by immunogenomic analysis19
A measure of case complexity for streamlining workflow in multidisciplinary tumor boards: Mixed methods development and early validation of the MeDiC tool19
LncRNA growth arrest‐specific transcript 5 targets miR‐21 gene and regulates bladder cancer cell proliferation and apoptosis through PTEN19
Postoperative intensity‐modulated radiation therapy reduces local recurrence and improves overall survival in III‐N2 non‐small‐cell lung cancer: A single‐center, retrospective study19
Development and validation of a prognostic nomogram for predicting cancer‐specific survival after radical cystectomy in patients with bladder cancer:A population‐based study19
First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer18
Fat mass and obesity‐associated protein regulates tumorigenesis of arecoline‐promoted human oral carcinoma18
Body mass index trajectories and prostate cancer risk: Results from the EPICAP study18
What is the role of lateral lymph node dissection in rectal cancer patients with clinically suspected lateral lymph node metastasis after preoperative chemoradiotherapy? A meta‐analysis and systematic18
Cost‐effectiveness of the Collaborative Care to Preserve Performance in Cancer (COPE) trial tele‐rehabilitation interventions for patients with advanced cancers18
Body mass index associated with childhood and adolescent high‐risk B‐cell acute lymphoblastic leukemia risk: A Children’s Oncology Group report18
Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer18
0.16650605201721